Alzheimer’s & Dementia: Translational Research & Clinical Interventions (Jan 2024)

New directions for Alzheimer's disease research from the Jackson Laboratory Center for Alzheimer's and Dementia Research 2022 workshop

  • Maria A. Telpoukhovskaia,
  • Thomas J. Murdy,
  • Olivia J. Marola,
  • Kevin Charland,
  • Michael MacLean,
  • Tain Luquez,
  • Alexandra M. Lish,
  • Sarah Neuner,
  • Amy Dunn,
  • Kristen D. Onos,
  • Jesse Wiley,
  • Derek Archer,
  • Matthew J. Huentelman,
  • Matthias Arnold,
  • Vilas Menon,
  • Alison Goate,
  • Linda J. Van Eldik,
  • Paul R. Territo,
  • Gareth R. Howell,
  • Gregory W. Carter,
  • Kristen M. S. O'Connell,
  • Catherine C. Kaczorowski,
  • the 2022 JAX CADR Workshop

DOI
https://doi.org/10.1002/trc2.12458
Journal volume & issue
Vol. 10, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract INTRODUCTION In September 2022, The Jackson Laboratory Center for Alzheimer's and Dementia Research (JAX CADR) hosted a workshop with leading researchers in the Alzheimer's disease and related dementias (ADRD) field. METHODS During the workshop, the participants brainstormed new directions to overcome current barriers to providing patients with effective ADRD therapeutics. The participants outlined specific areas of focus. Following the workshop, each group used standard literature search methods to provide background for each topic. RESULTS The team of invited experts identified four key areas that can be collectively addressed to make a significant impact in the field: (1) Prioritize the diversification of disease targets, (2) enhance factors promoting resilience, (3) de‐risk clinical pipeline, and (4) centralize data management. DISCUSSION In this report, we review these four objectives and propose innovations to expedite ADRD therapeutic pipelines.